RK-33

N/A

Report date: 2025/01/26 19:35:42
NME

Base Information

Drug NameRK-33
Drug Alias Namesmall molecule radiosensitizer (Natsar Pharmaceuticals)RK-33
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionATP-dependent RNA helicase DDX3X inhibitors
TargetsATP-dependent RNA helicase DDX3X
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Lung NeoplasmsMedulloblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNatsar Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNatsar Pharmaceuticals Inc
Inactive CompaniesJohns Hopkins Technology VenturesJohns Hopkins University
Active IndicationsCoronavirus Disease 2019 (COVID-19)Lung NeoplasmsMedulloblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A